Immunohistochemical analysis of HLDA9 Workshop antibodies against cell-surface molecules in reactive and neoplastic lymphoid tissues

Immunology Letters

Volumn 134, Issue 2, 2011, Pages 150-156

  Ramos Medina, Rocio ^a   Montes Moreno, Santiago ^a   Maestre, Lorena ^a   Cañamero, Marta ^a   Rodriguez Pinilla, Maria ^a   Lázaro, Adriana ^b   Roncador, Giovanna ^a  

^a Structural Biology and Biocomputing Programme   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

BAFF R; CCR6; Galectin 3; HVEM; Immunohistochemistry; TRAIL R2

Indexed keywords

B CELL ACTIVATING FACTOR RECEPTOR; CELL SURFACE PROTEIN; CHEMOKINE RECEPTOR CCR6; DEATH RECEPTOR 5; DIFFERENTIATION ANTIGEN; GALECTIN 3; HERPESVIRUS ENTRY MEDIATOR; HUMAN LEUKOCYTE DIFFERENTIATION ANTIGEN 9; UNCLASSIFIED DRUG;

ANTIBODY SPECIFICITY; ARTICLE; CONTROLLED STUDY; CUTANEOUS T CELL LYMPHOMA; DISEASE COURSE; FOLLICULAR LYMPHOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREGULATION; LARGE CELL LYMPHOMA; LYMPHOMA; MOLECULAR RECOGNITION; PERIPHERAL T CELL LYMPHOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; TISSUE MICROARRAY; TUMOR MICROENVIRONMENT;

ANTIBODIES, MONOCLONAL; ANTIGENS, SURFACE; B-CELL ACTIVATION FACTOR RECEPTOR; GALECTIN 3; HUMANS; IMMUNOCHEMISTRY; LYMPHOID TISSUE; LYMPHOMA; RECEPTORS, CCR6; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RECEPTORS, TUMOR NECROSIS FACTOR, MEMBER 14;

EID: 78650275183     PISSN: 01652478     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.imlet.2010.10.007     Document Type: Article

References (39)

1. Mason D., Andre P., Bensussan A., Buckley C., Civin C., Clark E., et al. CD antigens 2002. Blood 2002, 99:3877-3880.
2. Knapp W., Dorken B., Rieber P., Schmidt R.E., Stein H., von dem Borne A.E. CD antigens 1989. Blood 1989, 74:1448-1450.
3. Zola H. The 8th Human Leucocyte Differentiation Antigens Workshop: potential new CD molecules. J Biol Regul Homeost Agents 2002, 16:119-124.
4. Walczak H., Degli-Esposti M.A., Johnson R.S., Smolak P.J., Waugh J.Y., Boiani N., et al. TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBO J 1997, 16:5386-5397.
5. Daniels R.A., Turley H., Kimberley F.C., Liu X.S., Mongkolsapaya J., Ch'En P., et al. Expression of TRAIL and TRAIL receptors in normal and malignant tissues. Cell Res 2005, 15:430-438.
6. Clodi K., Wimmer D., Li Y., Goodwin R., Jaeger U., Mann G., et al. Expression of tumour necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptors and sensitivity to TRAIL-induced apoptosis in primary B-cell acute lymphoblastic leukaemia cells. Br J Haematol 2000, 111:580-586.
7. Koornstra J.J., Kleibeuker J.H., van Geelen C.M., Rijcken F.E., Hollema H., de Vries E.G., et al. Expression of TRAIL (TNF-related apoptosis-inducing ligand) and its receptors in normal colonic mucosa, adenomas, and carcinomas. J Pathol 2003, 200:327-335.
8. Keane M.M., Ettenberg S.A., Nau M.M., Russell E.K., Lipkowitz S. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Cancer Res 1999, 59:734-741.
9. Baba M., Imai T., Nishimura M., Kakizaki M., Takagi S., Hieshima K., et al. Identification of CCR6, the specific receptor for a novel lymphocyte-directed CC chemokine LARC. J Biol Chem 1997, 272:14893-14898.
10. Dieu M.C., Vanbervliet B., Vicari A., Bridon J.M., Oldham E., Ait-Yahia S., et al. Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites. J Exp Med 1998, 188:373-386.
11. Cook D.N., Prosser D.M., Forster R., Zhang J., Kuklin N.A., Abbondanzo S.J., et al. CCR6 mediates dendritic cell localization, lymphocyte homeostasis, and immune responses in mucosal tissue. Immunity 2000, 12:495-503.
12. Legler D.F., Loetscher M., Roos R.S., Clark-Lewis I., Baggiolini M., Moser B. B cell-attracting chemokine 1, a human CXC chemokine expressed in lymphoid tissues, selectively attracts B lymphocytes via BLR1/CXCR5. J Exp Med 1998, 187:655-660.
13. Krzysiek R., Lefevre E.A., Bernard J., Foussat A., Galanaud P., Louache F., et al. Regulation of CCR6 chemokine receptor expression and responsiveness to macrophage inflammatory protein-3α/CCL20 in human B cells. Blood 2000, 96:2338-2345.
14. Murphy K.M., Nelson C.A., Sedy J.R. Balancing co-stimulation and inhibition with BTLA and HVEM. Nat Rev Immunol 2006, 6:671-681.
15. Takenaka Y., Fukumori T., Raz A. Galectin-3 and metastasis. Glycoconj J 2004, 19:543-549.
16. Tsuboi K., Shimura T., Masuda N., Ide M., Tsutsumi S., Yamaguchi S., et al. Galectin-3 expression in colorectal cancer: relation to invasion and metastasis. Anticancer Res 2007, 27:2289-2296.
17. Sato S., Hughes R.C. Regulation of secretion and surface expression of Mac-2, a galactoside-binding protein of macrophages. J Biol Chem 1994, 269:4424-4430.
18. Perillo N.L., Marcus M.E., Baum L.G. Galectins: versatile modulators of cell adhesion, cell proliferation, and cell death. J Mol Med 1998, 76:402-412.
19. Chiu C.G., Strugnell S.S., Griffith O.L., Jones S.J., Gown A.M., Walker B., et al. Diagnostic utility of galectin-3 in thyroid cancer. Am J Pathol 2010, 176:2067-2081.
20. Sakaki M., Fukumori T., Fukawa T., Elsamman E., Shiirevnyamba A., Nakatsuji H., et al. Clinical significance of Galectin-3 in clear cell renal cell carcinoma. J Med Invest 2010, 57:152-157.
21. Konstantinov K.N., Robbins B.A., Liu F.T. Galectin-3, a beta-galactoside-binding animal lectin, is a marker of anaplastic large-cell lymphoma. Am J Pathol 1996, 148:25-30.
22. Suzuki O., Abe M. Cell surface N-glycosylation and sialylation regulate galectin-3-induced apoptosis in human diffuse large B cell lymphoma. Oncol Rep 2008, 19:743-748.
23. Thompson J.S., Bixler S.A., Qian F., Vora K., Scott M.L., Cachero T.G., et al. BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF. Science 2001, 293:2108-2111.
24. Mackay F., Schneider P., Rennert P., Browning J. BAFF AND APRIL: a tutorial on B cell survival. Annu Rev Immunol 2003, 21:231-264.
25. Batten M., Groom J., Cachero T.G., Qian F., Schneider P., Tschopp J., et al. BAFF mediates survival of peripheral immature B lymphocytes. J Exp Med 2000, 192:1453-1466.
26. Tardivel A., Tinel A., Lens S., Steiner Q.G., Sauberli E., Wilson A., et al. The anti-apoptotic factor Bcl-2 can functionally substitute for the B cell survival but not for the marginal zone B cell differentiation activity of BAFF. Eur J Immunol 2004, 34:509-518.
27. Castigli E., Wilson S.A., Scott S., Dedeoglu F., Xu S., Lam K.P., et al. TACI and BAFF-R mediate isotype switching in B cells. J Exp Med 2005, 201:35-39.
28. Mackay F., Woodcock S.A., Lawton P., Ambrose C., Baetscher M., Schneider P., et al. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 1999, 190:1697-1710.
29. Rodig S.J., Jones D., Shahsafaei A., Dorfman D.M. CCR6 is a functional chemokine receptor that serves to identify select B-cell non-Hodgkin's lymphomas. Hum Pathol 2002, 33:1227-1233.
30. Varona R., Cadenas V., Flores J., Martinez A.C., Marquez G. CCR6 has a non-redundant role in the development of inflammatory bowel disease. Eur J Immunol 2003, 33:2937-2946.
31. Varona R., Cadenas V., Gomez L., Martinez A.C., Marquez G. CCR6 regulates CD4+ T-cell-mediated acute graft-versus-host disease responses. Blood 2005, 106:18-26.
32. Lukacs N.W., Prosser D.M., Wiekowski M., Lira S.A., Cook D.N. Requirement for the chemokine receptor CCR6 in allergic pulmonary inflammation. J Exp Med 2001, 194:551-555.
33. Dellacasagrande J., Schreurs O.J., Hofgaard P.O., Omholt H., Steinsvoll S., Schenck K., et al. Liver metastasis of cancer facilitated by chemokine receptor CCR6. Scand J Immunol 2003, 57:534-544.
34. M'Hidi H., Thibult M.L., Chetaille B., Rey F., Bouadallah R., Nicollas R., et al. High expression of the inhibitory receptor BTLA in T-follicular helper cells and in B-cell small lymphocytic lymphoma/chronic lymphocytic leukemia. Am J Clin Pathol 2009, 132:589-596.
35. Harrop J.A., McDonnell P.C., Brigham-Burke M., Lyn S.D., Minton J., Tan K.B., et al. Herpesvirus entry mediator ligand (HVEM-L), a novel ligand for HVEM/TR2, stimulates proliferation of T cells and inhibits HT29 cell growth. J Biol Chem 1998, 273:27548-27556.
36. Zhai Y., Guo R., Hsu T.L., Yu G.L., Ni J., Kwon B.S., et al. LIGHT, a novel ligand for lymphotoxin beta receptor and TR2/HVEM induces apoptosis and suppresses in vivo tumor formation via gene transfer. J Clin Invest 1998, 102:1142-1151.
37. Yu P., Lee Y., Liu W., Chin R.K., Wang J., Wang Y., et al. Priming of naive T cells inside tumors leads to eradication of established tumors. Nat Immunol 2004, 5:141-149.
38. Paterson J.C., Tedoldi S., Craxton A., Jones M., Hansmann M.L., Collins G., et al. The differential expression of LCK and BAFF-receptor and their role in apoptosis in human lymphomas. Haematologica 2006, 91:772-780.
39. Rodig S.J., Shahsafaei A., Li B., Mackay C.R., Dorfman D.M. BAFF-R, the major B cell-activating factor receptor, is expressed on most mature B cells and B-cell lymphoproliferative disorders. Hum Pathol 2005, 36:1113-1119.